ERC Announces Interim Results from Phase 2 Trial of Immunotherapy ERC1671 (Gliovac) in Recurrent Glioblastoma Patients
Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)
This is the early results of a phase 2 randomized clinical trial for recurrent glioblastoma, which shows a remarkable improvement compared to historical controls (they do not discuss how the placebo group in the trial dd). 6 month survival rate was 100% in the trial compared to historical 33%. Median overall survival is 46 weeks compared to historical control of 23 weeks. Presumably some of the patients are still alive and the survivals should increase but they are already at double, and this is with a treatment that usually has minimal side effects.
Posted on: 08/23/2020
Click HERE to return to brain tumor news headlines